Publications by authors named "Paurus Irani"

Claim this Profile
R
Real-world study of Ceftazidime-Avibactam for the treatment of disease caused by bacteria: a plain language summary.
Alex Soriano, Philippe Montravers, Matteo Bassetti, Galina Klyasova, George Daikos, Paurus Irani

Future Microbiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: A Phase 4, multi-centre, open-label study.
Jinyi Yuan, Haihui Huang, Fei Guo, Aimin Li, NanYan Xu, Paurus Irani

J Glob Antimicrob Resist· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial.
John Bradley, Emmanuel Roilides, Margaret Tawadrous, Jean Li Yan, Elena Soto, Paurus Irani

J Pediatric Infect Dis Soc· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Ceftazidime‑Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta‑analysis.
Ryan K Shields, Juan P Horcajada, Shweta Kamat, Paurus M Irani, Margaret Tawadrous

Infect Dis Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis.
Ryan K Shields, Juan P Horcajada, Shweta Kamat, Paurus M Irani, Margaret Tawadrous

Infect Dis Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
Antoni Torres, Michele Wible, Margaret Tawadrous, Paurus Irani, Gregory G Stone

J Antimicrob Chemother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Use and Effectiveness of Ceftazidime-Avibactam in Real-World Clinical Practice: EZTEAM Study.
Alex Soriano, Philippe Montravers, Matteo Bassetti, Galina Klyasova, George Daikos, Paurus Irani

Infect Dis Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.
John E Mazuski, Florian Wagenlehner, Antoni Torres, Yehuda Carmeli, Joseph W Chow, Paurus Irani

Infect Dis Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review.
Alex Soriano, Yehuda Carmeli, Ali S Omrani, Luke S P Moore, Margaret Tawadrous, Paurus Irani

Infect Dis Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
James A Karlowsky, Krystyna M Kazmierczak, Maria Lavínea Novis de Figueiredo Valente, Elkin Lemos Luengas, Monique Baudrit, Paurus Irani

Braz J Infect Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by .
George L Daikos, Clóvis Arns da Cunha, Gian Maria Rossolini, Gregory G Stone, Nathalie Baillon-Plot, Paurus Irani

Antibiotics (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
Eszter Tichy, Antoni Torres, Matteo Bassetti, Thitima Kongnakorn, Roberto Di Virgilio, Paurus Irani

Clin Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A look at clinical trial design for new antimicrobials for the adult population.
Matteo Bassetti, Daniele Roberto Giacobbe, Maddalena Peghin, Paurus Irani

Expert Rev Clin Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK).
Neil Woodford, Li Xu-McCrae, Shazad Mushtaq, Houdini Ho Tin Wu, Matthew J Ellington, Paurus M Irani

J Antimicrob Chemother· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European and Russian physician awareness of best management approaches for infections due to antibiotic-resistant Gram-negative bacteria.
Paurus Irani, Tehseen Salimi, Robert Epstein, Megan Leone-Perkins, Ronald Aubert

Curr Med Res Opin· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atherogenic dyslipidemia.
C N Manjunath, Jayesh R Rawal, Paurus Mehelli Irani, K Madhu

Indian J Endocrinol Metab· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis